Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP185 | DOI: 10.1530/endoabs.49.EP185

ECE2017 Eposter Presentations: Adrenal and Neuroendocrine Tumours Endocrine tumours and neoplasia (50 abstracts)

Descriptive and survival study of 142 cases of gastroenteropancreatic neuroendocrine tumor (GEP-NETs) diagnosed at the Hospital Clínico San Carlos (HCSC)

Rona Penso 1 , Inés Jiménez-Varas 1 , Angela Amengual 1 , Lorea Herraiz 1 , Ane Azkutia 1 , Anna Ortolá 2 , Paz de Miguel 1 & José Angel Díaz 1


1Hospital Clinico San Carlos, Madrid, Spain; 2Hospital Clinico Universitario, Valladolid, Spain.


Introduction: Neuroendocrine tumors (NETs) constitute a very heterogeneous group of rare neoplasms, although their incidence has increased in recent years. We describe its evolution and survival.

Methods: Retrospective study. All patients with histopathological diagnosis of GEP-NETs performed at the HCSC between 2000 and 2016 were selected, data from the medical history were included. Statistical analysis were done with SPSS.

Results: One hundred and forty-two patients, 54.9% male, mean age 60.2 years (S.D. 19.7). The median follow-up time was 3.3 years (IR: 0.78–6.33). The most frequent locations were pancreatic (28.2%) and rectal (16.2%). The tumor stage was: I 47.2%, II 4.9%, III 13.4%, IV 34.5%. The initial stage (IS) presented positive correlation with the degree of differentiation (DD) (Cramer’s V 0.46, P <0.05) and with levels of Chromogranin A (Cramer’s V 0.37, P <0.05). 12% had progression and 64% died during follow-up (72% due to tumor). Overall survival at 5 years was 69 and 53% at 10 years. There were significant differences in survival according to location, with gallbladder and colon being the lowest (0 and 38% at 5 years, respectively). DD, IS and sex were also associated with survival (at 10 years: G1 95% vs G3 14.3% P<0.01, stage I 91% vs IV 28% P<0.01, median males 7.5 years vs 16.9 in females P 0.018). These differences were maintained after multivariate analysis in the case of DD and IS.

In stage IV survival was modified according to surgical treatment (operated median 5.9 years vs non-operated 0.64 years, P<0.01).

Conclusion: In our sample the overall mortality was high, despite having a low rate of progression. DD and IS were determinants of survival. In advanced stages surgical treatment improves survival significantly.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.